The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients

Scandinavian Journal of Urology and Nephrology

Volumn 37, Issue 1, 2003, Pages 77-82

  Cavdar, Caner ^a   Temiz, Ayşegul ^a   Yeniçerioǧlu, Yavuz ^a   Çalişkan, Sezer ^a   Çelik, Ali ^a   Sifil, Aykut ^a   Önvural, Banu ^a   Camsari, Taner ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Erythrocyte deformability; Hemodialysis; Iron; Oxidant stress

Indexed keywords

FERRIC HYDROXIDE SUCROSE; IRON; MALONALDEHYDE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG INFUSION; ERYTHROCYTE DEFORMABILITY; EVALUATION; FEMALE; GOOD GENERAL CONDITION; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; MALE; NORMAL VALUE; OXIDATIVE STRESS; PARAMETER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TASK PERFORMANCE; TREATMENT OUTCOME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTE DEFORMABILITY; FEMALE; FERRIC COMPOUNDS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; SUCROSE; TIME FACTORS;

EID: 0344211513     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365590310008758     Document Type: Article

References (21)

1. Cavdar C, Camsan T, Semin İ, Gönenc S and Açlkgo̧z O. Lipid peroxidation and antioxidant activity in chronic haemodialysis patients treated with recombinant human erythropoietin. Scand J Urol Nephrol 1997; 31: 371-5.
2. Richard M, Arnaud J, Jurkovitz C et al. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron 1991; 57: 10-15.
3. Matkovics B, Laszlo A, Varga SZ et al. Changes and correlations of antioxidant enzymes, lipid peroxidation and serum neutral lipids due to haemodialysis treatment in chronic uraemic patients. Int Urol Nephrol 1988; 20(5): 559-64.
4. Vijoen M, Oliveria A, Milne F. Physical properties of the red blood cells in chronic renal failure. Nephron 1991; 59: 271-8.
5. Rosenmund A, Binswanger U, Straub PW et al. Oxidative injury to erythrocytes, red cell rigidity and splenic hemolysis in hemodialyzed uremic patients. Ann Intern Med 1975; 82(4): 460-5.
6. Zachee P, Ferrant A, Daelemans R et al. Oxidative injury to erythrocytes, cell rigidity and splenic hemolysis in hemodialyzed patients before and during erythropoietin treatment. Nephron 1993; 65: 288-93.
7. Sommerburg O, Grune T, Hampl H et al. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Nephrol Dial Transplant 1998; 13: 2583-7.
8. Lim P, Wei YH, Yu YL and Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999; 14: 2680-7.
9. Fishbane S, Maesaka JK and Mittal SK. Is there material hazard to treatment with intravenous iron? Nephrol Dial Transplant 1999; 14: 2595-8.
10. Koutsouris D, Guillet D, Levievre R et al. Individual red blood cell transit times during flow through cylindrical micropores. Clin Hemorheol 1988; 8: 453-60.
11. Jain SK. Membrane lipid peroxidation in erythrocytes of the newborn. Clinica Chemica Acta 1986; 161: 301-6.
12. Silverberg DS, Blum M, Peer G, Kaplan E and Iaina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996; 72: 413-7.
13. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14(Suppl 5): 1-50.
14. Worwood M. Pathogenesis and management of haemochromatosis. Br J Haematol 1999; 105(Suppl 1): 16-8.
15. Bayes B, Sierra C, Pastor MC and Bonal I. Effect of intravenous iron therapy on oxidative stress in hemodialysis. Nephrol Dial Transplant 1998; 13(6): A206.
16. Geisser P, Baer M and Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Drug Res 1992; 42(II): 1439-52.
17. Forman S, Bischel M, Hochstein P. Erythrocyte deformability in uremic hemodialysed patients. Ann Intern Med 1973; 79: 841-3.
18. Ifere Go, Ifon ET, Ebong PE and Umoh IB. Abnormalities in adenosine triphosphatase of the erythrocyte membrane in iron deficiency anaemia. J Trace Elem Med Biol 1996; 10(3): 185-8.
19. Browne PV, Shalev O, Kuypers FA et al. Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia. J Clin Invest 1997 Sep 15; 100(6): 1459-64.
20. Martinez M, Vaya A, Alvarino J et al. Hemorheological alterations in patients with chronic renal failure. Effect of hemodialysis. Clin Hemorheol Microcirc 1999; 21(1): 1-6.
21. Macdougall IC. Intravenous administration of iron in epoetin-treated haemodialysis patients - which drugs, which regimen? Nephrol Dial Transplant 2000; 15: 1743-5.